Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Pyridostigmine + glycopyrrolate** is a combination of two drugs commonly used perioperatively to reverse neuromuscular blockade induced by nondepolarizing muscle relaxants. Pyridostigmine is an acetylcholinesterase inhibitor that increases acetylcholine at the neuromuscular junction, facilitating the reversal of muscle relaxation. Glycopyrrolate is an antimuscarinic agent that counteracts muscarinic side effects (such as bradycardia, excessive secretions, gastrointestinal stimulation) produced by acetylcholinesterase inhibitors. This combination is typically administered intravenously at the end of surgical procedures under general anesthesia. It is also used off-label in patients with myasthenia gravis to reduce the peripheral cholinergic side effects of pyridostigmine, such as excessive secretions[2][3][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pyridostigmine + glycopyrrolate.